Regeneron beats quarterly estimates on eczema drug demand
29 August 2024 Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the ...
Zacks.com on MSN6d
Regeneron to Report Q4 Earnings: Is a Beat in the Cards?Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...
Patients with the ultra-rare rare disease CHAPLE could have a first approved treatment in the summer, now that the FDA has started its review of Regeneron’s dug candidate pozelimab. CHAPLE ...
Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...
The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.
Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., Appeal Nos. 2024-1965, -1966, -2082, -2083 (Fed. Cir. Jan. 29, 2025) ...
The Tarrytown, New York-based company said it had net income of $8.06 per share. Earnings, adjusted for stock option expense and non-recurring costs, came to $12.07 per share. The results exceeded ...
and diabetic macular edema are under FDA review with a target action date of April 20, 2025, to potentially extend dosing intervals for Eylea HD up to every 24 weeks. Regeneron plans to submit a ...
NEW YORK (Reuters) - Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals, Illumina and 17 U.S. health systems will take a $320 million stake in the company as part ...
It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback